Noble Capital analyst Robert LeBoyer initiated coverage of NeuroSense with an Outperform rating and $9 price target. Lead product PrimeC has completed two Phase 2 trials for Amyotrophic Lateral Sclerosis and has a Phase 3 trial planned for early 2026, notes the analyst, who adds that initial results from a Phase 2 study in Alzheimer's disease showed "promising data."
